Skip to main content
SpringerLink
Log in

Quality of Life in Women with Ovarian Cancer

  • Chapter
  • First Online:
Advances in Diagnosis and Management of Ovarian Cancer

  • 402 Accesses

Abstract

Ovarian cancer and its treatments can have profound and diverse impacts on patients’ quality of life. Within research contexts, “health-related quality of life” (HRQL) is used as an umbrella term to encompass and assess all of these impacts. Specific impacts include physical symptoms and functioning impairment caused by the disease, and the psychological distress these cause, alongside the shock of the diagnosis and ongoing fear and uncertainty about the future. Distress may also arise after surgery and chemotherapy due to the side effects and physical changes that these treatments can cause. Some side effects may persist long after treatment ends, such as psychosexual issues and peripheral neuropathy. Standardised assessment of these issues, whether separately as specific patient-reported outcomes (PROs) or collectively under the umbrella term HRQL, using validated questionnaires in clinical trials can provide evidence to guide improvements in clinical practice. Such data can also inform patients about possible treatment impacts and assist patients to make treatment decisions. Standardised assessment is also useful in clinical practice, where an individual patient’s responses can facilitate communication with her clinician about her symptoms (physical and psychological) and their impact on her quality of life. In this chapter, we introduce key terminology and describe how ovarian cancer and its treatments affect patients’ HRQL in terms of the disease and treatment-related symptoms, functioning impairments, and psychological impact. Approaches to assessing HRQL in ovarian cancer research and clinical practice are described and an overview is provided of ongoing ovarian cancer clinical trials that include HRQL endpoints.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol. 1994;12(3):608–16.

    Article  PubMed  CAS  Google Scholar 

  2. Revicki DA, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9(8):887–900.

    Article  PubMed  CAS  Google Scholar 

  3. Food and Drug Administration. Patient reported outcome measures: use in medical product development to support labelling claims. MD: US Department of Health & Human Support Food & Drug Administration; 2009.

    Google Scholar 

  4. Australian Institute of Health and Welfare 2017. Cancer in Australia 2017. Cancer series no.100. Cat. no. CAN100. Canberra: AIHW.

    Google Scholar 

  5. Havrilesky LJ, et al. Patient preferences in advanced or recurrent ovarian cancer. Cancer. 2014;120(23):3651–9.

    Article  PubMed  Google Scholar 

  6. Goff B. Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012;55(1):36–42.

    Article  PubMed  Google Scholar 

  7. Khan A, Sultana K. Presenting signs and symptoms of ovarian cancer at a tertiary care hospital. J Pak Med Assoc. 2010;60(4):260–2.

    PubMed  Google Scholar 

  8. Power J, Brown L, Ritvo P. A qualitative study examining psychosocial distress, coping, and social support across the stages and phases of epithelial ovarian cancer. Health Care Women Int. 2008;29(4):366–83.

    Article  PubMed  Google Scholar 

  9. Au H-J, et al. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res. 2010;10(2):119–28.

    Article  PubMed  Google Scholar 

  10. Friedlander M, Mercieca-Bebber RL, King MT. Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. Ann Oncol. 2016;27(Suppl 1):i66–71.

    Article  PubMed  Google Scholar 

  11. Brenner MH, Curbow B, Legro MW. The proximal-distal continuum of multiple health outcome measures: the case of cataract surgery. Med Care. 1995;33(4 Suppl):As236–44.

    PubMed  CAS  Google Scholar 

  12. Stockler MR, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13):1309–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Chase DM, Wenzel L. Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):421–31.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet. 2006;95:161–92.

    Article  Google Scholar 

  15. Pomel C, et al. Cytoreductive surgery in ovarian cancer. Cancer Imaging. 2007;7(1):210–5.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Cuneo MG, et al. Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology. 2017;84:139–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Kendrick M, Ercolano E, McCorkle R. Interventions to prevent postoperative complications in women with ovarian cancer. Clin J Oncol Nurs. 2011;15(2):195–202.

    Article  PubMed  Google Scholar 

  18. Meraner V, et al. Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy. BMC Cancer. 2012;12:77.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Soo Hoo S, et al. Patient-reported outcomes after extensive (ultraradical) surgery for ovarian cancer: results from a prospective longitudinal feasibility study. Int J Gynecol Cancer. 2015;25(9):1599–607.

    Article  PubMed  Google Scholar 

  20. Greimel E, et al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecol Oncol. 2013;131(2):437–44.

    Article  PubMed  Google Scholar 

  21. Meyer LA, Shi Q, Lasala J, Iniesta MD, Lin HK, Nick AM, Williams L, Sun C, Wang XS, Lu KH, Ramirez PT. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol. 2019;152:501–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Webber K, Friedlander M. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:126–38.

    Article  PubMed  Google Scholar 

  23. King MT, et al. Measuring what matters MOST: validation of the measure of ovarian symptoms and treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Qual Life Res. 2018;27(1):59–74.

    Article  PubMed  Google Scholar 

  24. Jayde V, Boughton M, Blomfield P. The experience of chemotherapy-induced alopecia for Australian women with ovarian cancer. Eur J Cancer Care. 2013;22(4):503–12.

    Article  CAS  Google Scholar 

  25. Domenici L, et al. Sexual health and quality of life assessment among ovarian cancer patients during chemotherapy. Oncology. 2016;91(4):205–10.

    Article  PubMed  Google Scholar 

  26. Shinde S, et al. Disease-free ovarian cancer patients report severe pain and fatigue over time: prospective quality of life assessment in a consecutive series. Eur J Gynaecol Oncol. 2015;36(2):155–60.

    PubMed  CAS  Google Scholar 

  27. Ezendam NP, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135(3):510–7.

    Article  PubMed  Google Scholar 

  28. Le-Rademacher J, Kanwar R, Seisler D, Pachma DR, Qin R, Abyzov A, Ruddy KJ, Banck MS, Lavoie Smith EM, Dorsey AG, Aaronson NK, Sloan J, Loprinzi CL, Beutler AS. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced periopheral neuropahty in NCCTG/Alliance clinical trials. Support Care Cancer. 2017;25:3537–44.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kober KM, et al. Phenotypic characterization of paclitaxel-induced peripheral neuropathy in cancer survivors. J Pain Symptom Manag. 2018;56:908–19.

    Article  Google Scholar 

  30. Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckman NF, Stoyles S, Faithfull S. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;23:2604–12.

    Article  Google Scholar 

  31. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced cancer. J Clin Oncol. 2001;19(5):1266–74.

    Article  PubMed  CAS  Google Scholar 

  32. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;1:CD005340.

    Google Scholar 

  33. Rustin GJS, Van der Burg MEL, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MKB, Swart AM. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955):a randomised trial. Lancet. 2010;376:155–1163.

    Article  Google Scholar 

  34. Anderson C, Carter J, Nattress K, Beale P, Philp S, Harrison J, Jurasjova I. “The Booklet Helped Me Not to Panic”: a pilot of a decision aid for symptomatic women with ovarian cancer with rising CA-125 levels. Int J Gynecol Cancer. 2011;21:737–43.

    PubMed  Google Scholar 

  35. Rossi L, et al. Bevacizumab in ovarian cancer: a critical review of phase III studies. Oncotarget. 2017;8(7):12389–405.

    Article  PubMed  Google Scholar 

  36. Ledermann J, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.

    Article  PubMed  CAS  Google Scholar 

  37. Ledermann JA, et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016;115(11):1313–20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinzo D, Joly F, Pujade-Lauraine E. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet. 2018;19:1126–34.

    Article  Google Scholar 

  39. Watts S, et al. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2015;5(11):e007618.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Shand LK, et al. Symptoms of posttraumatic stress in Australian women with ovarian cancer. Psycho-Oncology. 2015;24(2):190–6.

    Article  PubMed  Google Scholar 

  41. Ozga M, et al. A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care. 2015;13(6):1771–80.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Whicker M, et al. Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am J Obstet Gynecol. 2017;217(4):395–403.

    Article  PubMed  Google Scholar 

  43. Sun CC, Frumovitz M, Bodurka DC. Quality of life and gynecologic malignancies. Curr Oncol Rep. 2005;7:459–65.

    Article  PubMed  Google Scholar 

  44. Carter J, et al. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol Oncol. 2005;97(1):90–5.

    Article  PubMed  Google Scholar 

  45. Schover LR. Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors. A review. Med Pediatr Oncol. 1999;33:53–9.

    Article  PubMed  CAS  Google Scholar 

  46. Liavaag AH, et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol. 2008;108(2):348–54.

    Article  PubMed  Google Scholar 

  47. Kim SI, et al. Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women. J Gynecol Oncol. 2015;26(2):148–54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Fitch MI, Steele R. Identifying supportive care needs of women with ovarian cancer. Can Oncol Nurs J. 2010;20(2):66–74.

    Article  PubMed  Google Scholar 

  49. Roland KB, et al. A literature review of the social and psychological needs of ovarian cancer survivors. Psycho-Oncology. 2013;22(11):2408–18.

    Article  PubMed  Google Scholar 

  50. Donovan HS, et al. Web-based symptom management for women with recurrent ovarian cancer: a pilot randomized controlled trial of the WRITE Symptoms intervention. J Pain Symptom Manag. 2014;47(2):218–30.

    Article  Google Scholar 

  51. Lanceley A, et al. Ovarian cancer follow-up: a preliminary comparison of 2 approaches. Int J Gynecol Cancer. 2017;27(1):59–68.

    Article  PubMed  Google Scholar 

  52. Hwang KH, Cho OH, Yoo YS. The effect of comprehensive care program for ovarian cancer survivors. Clin Nurs Res. 2016;25(2):192–208.

    Article  PubMed  Google Scholar 

  53. Mizrahi D, et al. An exercise intervention during chemotherapy for women with recurrent ovarian cancer: a feasibility study. Int J Gynecol Cancer. 2015;25(6):985–92.

    Article  PubMed  Google Scholar 

  54. Ponto JA, Barton D. Husbands’ perspective of living with wives’ ovarian cancer. Psycho-Oncology. 2008;17(12):1225–31.

    Article  PubMed  Google Scholar 

  55. Frost MH, et al. Spiritual well-being and quality of life of women with ovarian cancer and their spouses. [Erratum appears in J Support Oncol. 2012 May-Jun;10(3):131]. J Support Oncol. 2012;10(2):72–80.

    Article  PubMed  Google Scholar 

  56. Butow PN, et al. Caring for women with ovarian cancer in the last year of life: a longitudinal study of caregiver quality of life, distress and unmet needs. Gynecol Oncol. 2014;132(3):690–7.

    Article  PubMed  Google Scholar 

  57. Aaronson NK, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

    Article  PubMed  CAS  Google Scholar 

  58. Flechtner H, Bottomley A. Quality of life assessment and research in the EORTC (European Organisation for Research and Treatment of Cancer). Oncologie. 2006;8(5):443–6.

    Article  Google Scholar 

  59. Cherny NI, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547–73.

    Article  PubMed  CAS  Google Scholar 

  60. Schnipper LE, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563–77.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Gilbert A, et al. Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecol Oncol. 2015;136(3):429–39.

    Article  PubMed  Google Scholar 

  62. Snyder CF, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21(8):1305–14.

    Article  PubMed  Google Scholar 

  63. Valderas JM, et al. The impact of measuring patient-reported outcomes in clinical practice: a systematic review of the literature. Qual Life Res. 2008;17(2):179–93.

    Article  PubMed  CAS  Google Scholar 

  64. Snyder CF, Watson ME, Jackson JD, Cella D, Halyard MY. Patient-reported outcome instrument selection: designing a measurement strategy. Value Health. 2007;10(Suppl 2):76–85.

    Article  Google Scholar 

  65. PROQOLID Patient-Reported Outcome and Quality of Life Instruments Database 2016. Mapi Research Trust [Internet].

    Google Scholar 

  66. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:171–84.

    Article  PubMed  Google Scholar 

  67. Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. Oxford: Oxford University Press; 1996.

    Google Scholar 

  68. Cella D, et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.

    Article  PubMed  CAS  Google Scholar 

  69. Greimel E, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39(10):1402–8.

    Article  PubMed  CAS  Google Scholar 

  70. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, Gershenson DM. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001;19:1809–17.

    Article  PubMed  CAS  Google Scholar 

  71. Cella D, Paul D, Yount S, Winn R, Chang C-H, Banik D, Weeks J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investig. 2003;21:526–35.

    Article  Google Scholar 

  72. Beaumont J, et al. Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer. J Clin Oncol. 2007;25(18_Suppl):16021.

    Article  Google Scholar 

  73. Jensen SE, et al. Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18). Gynecol Oncol. 2015;136(2):317–22.

    Article  PubMed  Google Scholar 

  74. Calhoun EA, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13(6):741–8.

    PubMed  CAS  Google Scholar 

  75. Cella D, et al. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer. 2003;98(4):822–31.

    Article  PubMed  CAS  Google Scholar 

  76. King MT, et al. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. Int J Gynecol Cancer. 2014;24(5):865–73.

    Article  PubMed  Google Scholar 

  77. Revicki D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–9.

    Article  PubMed  Google Scholar 

  78. Mercieca-Bebber R, et al. The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. Qual Life Res. 2016;25(10):2457–65.

    Article  PubMed  Google Scholar 

  79. Mercieca-Bebber R, et al. The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Related Outcome Meas. 2018;9:353–67.

    Article  Google Scholar 

  80. Calvert M, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA. 2018;319(5):483–94.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Sydney, Faculty of Science,School of Psychology, Sydney, NSW, Australia

    Rachel Campbell BPsych, MSc (ClinPsych), PhD, Madeleine T. King BSc (hons), PgDip MedStats, PhD, Margaret-Ann Tait BAS (Psych), MSc (CoachPsych) & Claudia Rutherford BPsych, PhD

  2. NHMRC Clinical Trials Centre, Faculty of Medicine, University of Sydney, Sydney, NSW, Australia

    Yeh Chen Lee MBBS, BMedSci, FRACP

  3. Prince of Wales Hospital, Sydney, NSW, Australia

    Yeh Chen Lee MBBS, BMedSci, FRACP

  4. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

    Linda Mileshkin MBBS, MD, FRACP, MBioeth

Authors
  1. Rachel Campbell BPsych, MSc (ClinPsych), PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Madeleine T. King BSc (hons), PgDip MedStats, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yeh Chen Lee MBBS, BMedSci, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Linda Mileshkin MBBS, MD, FRACP, MBioeth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Margaret-Ann Tait BAS (Psych), MSc (CoachPsych)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Claudia Rutherford BPsych, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachel Campbell BPsych, MSc (ClinPsych), PhD .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Joan and Sanford Weill Cornell University Medical Center - New York-Presbyterian Hospital and Sandra and Edward Meyer Cancer Center- Cornell University, New York, NY, USA

    Samir A. Farghaly

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Campbell, R., King, M.T., Lee, Y.C., Mileshkin, L., Tait, MA., Rutherford, C. (2022). Quality of Life in Women with Ovarian Cancer. In: Farghaly, S.A. (eds) Advances in Diagnosis and Management of Ovarian Cancer. Springer, Cham. https://doi.org/10.1007/978-3-031-09169-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-09169-8_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-09168-1

  • Online ISBN: 978-3-031-09169-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation